Cantor Fitzgerald sets USD 18 target for Novavax stock

Published on 10/27/2026 at 21:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novavax posted USD 57.00 million revenue in second quarter 2026, down from USD 239.00 million. Novavax stock costs EUR 8.96 on October 27, 2026.

Analyst target and quarterly revenue

Cantor Fitzgerald assigned Novavax a Buy rating and a USD 18.00 target on October 26, 2026.
Novavax reported USD 57.00 million in second-quarter 2026 revenue versus USD 239.00 million a year earlier.
Novavax stock costs EUR 8.96 at Lang & Schwarz on October 27, 2026 at 9:28 p.m. CEST.
Novavax is scheduled to report third-quarter 2026 results on November 5, 2026.

NVAX, US6700024010, Illustration mit AI erstellt.

Novavax (ISIN US6700024010) received a Buy rating and a USD 18.00 price target from Cantor Fitzgerald on October 26, 2026, according to Markets Insider. The target is materially above the current U.S. quotation, while the company remains focused on partnerships around its Matrix-M vaccine adjuvant. Novavax stock was trading at EUR 8.96 at Lang & Schwarz on October 27, 2026 at 9:28 p.m. CEST.

Revenue fell after a strong comparison

Novavax reported USD 57.00 million in total revenue for the second quarter of 2026, compared with USD 239.00 million in the second quarter of 2025. The result included USD 19.00 million in product sales, which increased 76.00 percent year over year, and USD 36.00 million related mainly to Sanofi research and development reimbursements and amortization, according to the company's earnings-call transcript published by Yahoo Finance on August 6, 2026.

What does the target imply?

Cantor Fitzgerald's USD 18.00 target compares with a Nasdaq quotation of USD 10.02 on October 27, 2026 at 4:00 p.m. ET. Novavax's 52-week range was USD 6.20 to USD 13.39, and its market capitalization was USD 1.7 billion on the same date. The Nasdaq-listed company operates in biotechnology and develops vaccines and vaccine technologies.

Results date is November 5

Novavax is scheduled to report third-quarter 2026 results on November 5, 2026, according to Barron's. The upcoming report will put the company's 2026 revenue framework and partner-related revenue under renewed scrutiny. The second-quarter transcript said adjusted full-year 2026 revenue was expected between USD 235.00 million and USD 275.00 million.

Market view stays divided

The latest analyst coverage shows a wide range of expectations. Cantor Fitzgerald's USD 18.00 target stands above the USD 10.75 consensus target cited by Markets Insider, while Bank of America maintained a USD 8.00 target on October 23, 2026. That spread makes the November report particularly important for judging execution against the partnership strategy.

Trading level after hours

Novavax stock was trading at EUR 8.96 at Lang & Schwarz on October 27, 2026 at 9:28 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Novavax stock.